Empiric treatment with aspirin and ticagrelor is the most cost-effective strategy in patients with minor stroke or transient ischemic attack.
Kaavya NarasimhaluJeremy ChanYoong Kwei AngDeidre Anne De SilvaKelvin Bryan TanPublished in: International journal of stroke : official journal of the International Stroke Society (2023)
This study suggests that in patients with minor stroke and TIA planned for dual antiplatelet regimens, empiric ticagrelor and aspirin is the most cost-effective treatment regimen. If ticagrelor is not available, genotype guided therapy is the most cost-effective treatment regimen if the LOF prevalence in the population is more than 48%.
Keyphrases
- acute coronary syndrome
- antiplatelet therapy
- percutaneous coronary intervention
- low dose
- atrial fibrillation
- st elevation myocardial infarction
- st segment elevation myocardial infarction
- stem cells
- coronary artery disease
- cardiovascular disease
- oxidative stress
- bone marrow
- mesenchymal stem cells
- replacement therapy
- blood brain barrier
- brain injury
- cell therapy